Breaking News

Amgen Licenses DSM’s XD Cell Culture Patents

January 15, 2013

Technology is applicable to multiple biological products

DSM Pharmaceutical Products has signed a non-exclusive license agreement with Amgen providing access to its XD high cell density process patents. XD technology is a highly intensified cell culture process with typical titer achievement of 8-to-10 times higher than current standard biomanufacturing processes, according to the company. It is applicable for multiple biological products including proteins, fusion proteins and antibodies, as well as the full spectrum of mammalian cell systems. Financial terms were not disclosed.
 
Karen King, president of DSM Biologics, said, “We are pleased to enter into this license agreement with Amgen, a global leader in biopharmaceutical drug development and manufacturing. We believe our proprietary XD technology will play an important role in the next generation of biopharmaceutical manufacturing."
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems